Welcome to the Pacific Edge Investor Centre. Here you will find useful information about being a shareholder of our company.
See the latest news and presentations, keep up to date with our newsletters and shareholder reports, find out when we are holding shareholder meetings and check up on our share price.
Pacific Edge is a publicy listed company on the NZX: listed as PEB.
- Value $00,000.000
- Volume 00,000
- Capitalisation $000,000
- Open $0.000
- Close $0.000
- High $0.000
- Low $0.000
Data up to date as of 00-00-0000 00:00
Callaghan Innovation Growth Grant for Pacific Edge
Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) is pleased to advise that it has received an additional grant of up to $3 million to its existing Growth Grant from Callaghan Innovation to enable further research and development of its leading edge cancer diagnostics technology. [read more]
Significant Increase in Clinical Utility from Use of Cxbladder
An international study demonstrates compelling changes in urologists’ clinical decisions, with use of Cxbladder Triage and Cxbladder Detect leading to fewer total tests and less invasive procedures, implying a reduction in healthcare costs and an improved experience and outcome for patients. [read more]
Cxbladder Monitor Significantly Outperforms FDA Approved Urine Tests for Bladder Cancer
The prestigious international journal Urological Oncology, has accepted for publication a scientific and clinical paper validating the superior performance of Pacific Edge’s Cxbladder Monitor test for the surveillance of patients who are being managed following treatment for bladder cancer. [read more]
Reports and Presentations
For further investor information on Pacific Edge our recent annual reports, investor presentations and investment research reports are available for download below